Cardiology

Type 2 diabetes patient outcomes including heart failure, stroke, and myocardial infarction were weighed between the 2 popular drug classes.

A study of the massive 2005 trial data found that fenofibrate-targeted biomarkers are closely associated to cardiovascular risks in patients with T2D.

A study into the impact of the timing of glucose blood readings has found that being 15 to 25 minutes late can almost double a patient's risk of hypoglycemia.

A decision for icosapent ethyl's sNDA is not expected to come from the FDA until September, but excitement surrounding the drug is at all-time high.

Early initiation of GLP-1RA and SGLT2 in patients with T2D resulted in higher odds for long term HbA1C control and for lower CV risk factors.

The longest clinical assessment of a GLP-1 receptor agonist for cardiovascular outcomes showed a 12% decrease in MACE versus placebo.

An age-stratified analysis of Swedish national registry data found that myocardial infarction and heart failure rates may even be more prevalent in patients with T1D.

Sue Kirkman, MD, professor of medicine at UNC Chapel Hill, discusses the results of a study she led that attempted to create a method of identifying what type of diabetes through EHR data.

John Buse, MD, professor of medicine at UNC Chapel Hill, discusses the results and implications of the PIONEER 7 trial.

It's been 5 years since the FDA approved empagliflozin, and 4 since the major outcomes findings. What is its role in diabetes care today?

The three-year trial reported that initial weight loss plus 1 of any 4 diet and exercise programs is associated with major benefits for at-risk patients.

A review of REDUCE-IT data prior to an FDA supplemental new drug application decision shows the unprecedented benefit of the fish oil therapy.

Todd Hobbs, MD, chief medical officer of Novo Nordisk North America, discusses the results of PIONEER 4 at ADA 2019 in San Francisco, CA.

Todd Hobbs, MD, chief medical officer at Novo Nordisk North America, discusses what prompted Novo Nordisk to create oral semaglutide.

Todd Hobbs, MD, CMO of Novo Nordisk, discusses the findings of the PIONEER 2 study.

A new study which considered the suggested association between type 2 diabetes and vitamin D deficiency did not show a statistically significant reduction of patient risk.

Investigators found that expansion states had a median of 4.3 fewer deaths per 100,000 residents than nonexpansion states.

Amarin announced the FDA had granted their sNDA for icosapent ethyl to reduce residual CV risk in patients with statin-managed LDL-C cholesterol.

The new occluder, which can repair both small and large cardiovascular defects, received premarket approval.

Analyses of more than 2 million patients found that preterm and early births were associated with an increased risk of ischemic heart disease.

A recent study examines the association between new-onset atrial fibrillation and aortic valve replacements and transcatheter aortic valve implantations.

A study of more than 74,000 in China from 2006 to 2015 found that cardiovascular health scores are associated with subsequent risk of CVD events.

A recent study has found that consumption of coffee may not be as bad as previous studies have portrayed.

BioMarin announced the investigative gene therapy reached pre-specified criteria for Factor VIII levels in adult patients with severe hemophilia A.

The signs and symptoms of the rare, chronic condition are not consistently detected in the first line of care.